Krop Julie 4

What Happened Julie Krop, a director of Aquestive Therapeutics (AQST), received a grant of derivative awards covering 50,500 shares on June 10, 2026. The filing reports an acquisition price of $0.00 (total reported value $0) and classifies the grant as a derivative award. The award vests 100% on June 10, 2027, subject to her continued service through that date.

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (timely).
• Award type: Derivative grant covering 50,500 shares; reported price $0.00; total reported value $0.
• Vesting: 100% of the underlying shares vest on June 10, 2027, contingent on continuous service (per footnote).
• Shares owned after transaction: Not specified in the filing.
• No 10b5-1 plan, tax withholding, or sale was reported in this filing.

Context This was a compensation-related award (derivative/option-style grant), not a market purchase or sale — it does not represent immediate proceeds or a disposition. The award will only convert into exercisable/vested shares if vesting conditions are met; retail investors typically view grants as routine executive/director compensation rather than a direct signal to buy or sell stock.